Schneyer J J, Goodman L I, Borgen L A
J Clin Pharmacol. 1976 Jul;16(7):377-83. doi: 10.1002/j.1552-4604.1976.tb01536.x.
Thirty anxious, neurotic patients were treated in a general practice setting with single-blind placebo for one week followed by two weeks of double-blind treatment with either placebo or 40 or 80 mg/day ripazepam (CI-683), a new potential antianxiety agent of the pyrazolodiazepinone series. As rated by both physician and patient, ripazepam was found significantly superior to placebo at both dosage levels. Some evidence of greater improvement at 80 mg/day than at 40 mg/day was also obtained. The drug appeared to be well tolerated, with side effects reported by only four patients.
30名焦虑、神经质患者在普通诊所接受治疗，先单盲服用安慰剂一周，随后双盲服用安慰剂或40毫克/天或80毫克/天的瑞普唑仑（CI - 683，一种新的潜在抗焦虑药，属于吡唑并二氮杂酮系列）两周。经医生和患者评定，两个剂量水平的瑞普唑仑均显著优于安慰剂。也获得了一些证据表明，80毫克/天的剂量比40毫克/天的剂量改善效果更佳。该药物耐受性良好，仅4名患者报告有副作用。
